AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 221 min read$MEDP

Medpace forecasts 2026 EPS of $17.97-$18.32 as $1B buyback authorization replaces prior program (NASDAQ:MEDP)

Medpace (MEDP) forecasts 2026 EPS of $17.97-$18.32, announces $1B buyback program. Q3 2026 saw record net new business awards, strong RFP activity, and high win rate, according to management.

Original reporting
seekingalpha.com
Published Oct 22, 2026, 3:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 3:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MEDP
Bullish
high confidence
Mentioned
$MEDP
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MEDPBullishMed
01

Why it matters

The new EPS guidance and buyback suggest confidence in pipeline and cash generation, which could attract investors seeking growth in the CRO space.

02

Market read

Fresh guidance and capital return plan provide a clear catalyst for MEDP traders.

03

What to watch

Potential dilution from future financing needs or execution risk on the projected earnings.

Relevance 7/10Novelty 7/10Timing: post‑market release

Background

Medpace is a contract research organization serving biotech and pharmaceutical companies.

Company-level read

Ticker impact

$MEDPBullishHigh confidence
Context

Medpace disclosed FY2026 EPS guidance of $17.97‑$18.32 and announced a $1 B share buyback authorization, new information not previously reported.

Expected impact

potential upside as investors price in the buyback and strong EPS outlook

Evidence & confidence

The EPS range and $1 B buyback are fresh, material data for a small‑cap biotech services firm, likely to attract buying pressure.

Market effects

Sector

May lift sentiment for contract research organizations and biotech service providers.

Regional

Limited to U.S. small‑cap and biotech sectors.

Global

Minimal global impact beyond niche biotech services market.

Counterpoint

What could challenge this read

If the guidance is already priced in, the buyback may not move the stock and could signal limited cash flow.

Key entities

  • company
    Medpace

    U.S. listed contract research organization (NASDAQ:MEDP).

Read at source← All news

StoryMedpace Reports Q3 Earnings Beat and Authorizes $1 Billion Buyback

Also covered by

4 outlets

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min
OCT 22
$MEDPHighAI 8/10

Why is Medpace stock sliding today?

Medpace Holdings Inc (MEDP) fell 1.6% in after-hours trading after its Q3 2026 earnings report. Adjusted EPS of $4.84 beat estimates, but full-year revenue guidance of $2.835B-$2.855B missed expectations. The board replaced a $527M stock buyback program with a $1B program. Insiders sold $467M in shares over the past year. The S&P 500, Dow Jones, and NASDAQ also declined during regular trading.

investing.com2 min